The global human metapneumovirus (HMPV) testing market is experiencing significant growth, driven by the increasing incidence of respiratory infections, particularly in vulnerable populations such as children and the elderly. Molecular diagnostic tests, such as RT-PCR and real-time PCR, are widely adopted for their high accuracy and sensitivity in detecting HMPV infections. The market is further fueled by advancements in rapid diagnostic tests (RDTs), which provide quicker results and are expected to drive demand in point-of-care (POC) settings.
Technological innovation is a key factor, with the development of next-generation sequencing (NGS) and CRISPR-based diagnostic tools offering more precise and cost-effective testing solutions. Hospitals, diagnostic laboratories, and research institutes are the primary end users of these tests, although point-of-care centers and home healthcare providers are witnessing increased adoption of rapid testing methods.
